MX2017001908A - Metodo para el tratamiento de la depresion. - Google Patents
Metodo para el tratamiento de la depresion.Info
- Publication number
- MX2017001908A MX2017001908A MX2017001908A MX2017001908A MX2017001908A MX 2017001908 A MX2017001908 A MX 2017001908A MX 2017001908 A MX2017001908 A MX 2017001908A MX 2017001908 A MX2017001908 A MX 2017001908A MX 2017001908 A MX2017001908 A MX 2017001908A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- depression
- patient
- allele
- esketamine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000020401 Depressive disease Diseases 0.000 title abstract 2
- 108700028369 Alleles Proteins 0.000 abstract 3
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 abstract 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 abstract 2
- 229960000450 esketamine Drugs 0.000 abstract 2
- 229960003299 ketamine Drugs 0.000 abstract 2
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 238000003205 genotyping method Methods 0.000 abstract 1
- 239000002858 neurotransmitter agent Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Otolaryngology (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere a un método para el tratamiento de la depresión, por ejemplo, la depresión resistente al tratamiento; en donde el régimen de tratamiento se ajusta en dependencia de del genotipo del paciente en el polimorfismo de un solo nucleótido (SNP) rs4306882; específicamente, el método comprende determinar la presencia de un alelo G o T en rs4306882, y la administración de un régimen de dosificación de ketamina o esketamina, en donde el régimen de dosificación se ajusta para proporcionar una dosis más alta y/o de mayor frecuencia de la ketamina o la esketamina a aquellos pacientes con el alelo G (en lugar del alelo T) en el sitio polimórfico de rs4306882; adicionalmente, se describe un método para predecir si un paciente que sufre de depresión está predispuesto genéticamente a responder probablemente a los antidepresivos que bloquean la recaptura de los neurotransmisores monoamina, que comprende el genotipado de dicho paciente para determinar el genotipo del paciente en el SNP rs4306882.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462036896P | 2014-08-13 | 2014-08-13 | |
| PCT/US2015/044830 WO2016025581A1 (en) | 2014-08-13 | 2015-08-12 | Method for the treatment of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017001908A true MX2017001908A (es) | 2017-08-08 |
Family
ID=55301311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001908A MX2017001908A (es) | 2014-08-13 | 2015-08-12 | Metodo para el tratamiento de la depresion. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10098854B2 (es) |
| EP (1) | EP3179993B1 (es) |
| JP (1) | JP6545788B2 (es) |
| KR (1) | KR20170040800A (es) |
| CN (1) | CN106714789A (es) |
| AU (2) | AU2015301782B2 (es) |
| CA (1) | CA2957926A1 (es) |
| IL (2) | IL250490A0 (es) |
| MA (1) | MA40462A (es) |
| MX (1) | MX2017001908A (es) |
| WO (1) | WO2016025581A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014152196A1 (en) | 2013-03-15 | 2014-09-25 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| ES2897453T3 (es) | 2013-09-13 | 2022-03-01 | Univ Chiba Nat Univ Corp | Aplicación de R-ketamina y sal de la misma como productos farmacéuticos |
| EP3094312B1 (en) * | 2014-01-14 | 2019-03-13 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| US11191734B2 (en) | 2015-06-27 | 2021-12-07 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| WO2019094596A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| CA3086478A1 (en) * | 2017-12-22 | 2019-06-27 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| PT3505157T (pt) | 2017-12-29 | 2022-02-18 | Celon Pharma Sa | Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento |
| WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| EP3813808A4 (en) | 2018-05-04 | 2022-01-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| EP3628313B1 (en) * | 2018-09-28 | 2025-02-12 | Novohale Therapeutics, LLC | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| WO2020154362A1 (en) | 2019-01-23 | 2020-07-30 | The Regent Of The University Of Michigan | Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors |
| IL318198A (en) | 2019-03-05 | 2025-03-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| WO2021262871A1 (en) * | 2020-06-25 | 2021-12-30 | Greenway Dna Inc. | Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| AU758679B2 (en) | 1998-07-24 | 2003-03-27 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| CA2529857A1 (en) | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
| CN101466364A (zh) | 2006-03-22 | 2009-06-24 | 纽约大学西奈山医学院 | 鼻内施用氯胺酮治疗抑郁症 |
| AU2007253684A1 (en) | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Treatment for depressive disorders |
| DE102007009888A1 (de) * | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| WO2009131794A1 (en) | 2008-03-27 | 2009-10-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| EP2582366B1 (en) | 2010-06-15 | 2015-10-28 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| BR112014011491A2 (pt) | 2011-11-14 | 2017-05-09 | Nestec Sa | ensaios e métodos para seleção de um regime de tratamento para um indivíduo com depressão |
| MX2014010939A (es) * | 2012-03-12 | 2014-11-13 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento. |
| MX2015002378A (es) | 2012-08-23 | 2015-09-25 | Stuart L Weg | Composicion ansiolitica, formulacion y metodo de uso. |
| NZ713300A (en) | 2013-04-12 | 2020-05-29 | Icahn School Med Mount Sinai | Method for treating post-traumatic stress disorder |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
-
2015
- 2015-08-12 WO PCT/US2015/044830 patent/WO2016025581A1/en not_active Ceased
- 2015-08-12 EP EP15831762.8A patent/EP3179993B1/en active Active
- 2015-08-12 MX MX2017001908A patent/MX2017001908A/es unknown
- 2015-08-12 AU AU2015301782A patent/AU2015301782B2/en not_active Ceased
- 2015-08-12 CN CN201580043454.XA patent/CN106714789A/zh active Pending
- 2015-08-12 MA MA040462A patent/MA40462A/fr unknown
- 2015-08-12 US US14/824,513 patent/US10098854B2/en active Active
- 2015-08-12 JP JP2017507823A patent/JP6545788B2/ja active Active
- 2015-08-12 KR KR1020177006277A patent/KR20170040800A/ko not_active Ceased
- 2015-08-12 CA CA2957926A patent/CA2957926A1/en not_active Abandoned
-
2017
- 2017-02-07 IL IL250490A patent/IL250490A0/en active IP Right Grant
-
2020
- 2020-12-03 AU AU2020281101A patent/AU2020281101A1/en not_active Abandoned
- 2020-12-21 IL IL279627A patent/IL279627A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3179993A1 (en) | 2017-06-21 |
| EP3179993A4 (en) | 2018-03-28 |
| EP3179993B1 (en) | 2021-01-20 |
| AU2015301782A1 (en) | 2017-03-02 |
| AU2020281101A1 (en) | 2021-01-07 |
| KR20170040800A (ko) | 2017-04-13 |
| CA2957926A1 (en) | 2016-02-18 |
| IL250490A0 (en) | 2017-03-30 |
| WO2016025581A1 (en) | 2016-02-18 |
| AU2015301782B2 (en) | 2020-09-03 |
| US20160045455A1 (en) | 2016-02-18 |
| JP6545788B2 (ja) | 2019-07-17 |
| CN106714789A (zh) | 2017-05-24 |
| MA40462A (fr) | 2017-06-21 |
| IL279627A (en) | 2021-03-01 |
| US10098854B2 (en) | 2018-10-16 |
| JP2017524719A (ja) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001908A (es) | Metodo para el tratamiento de la depresion. | |
| MX2016005003A (es) | Marcadores geneticos predictivos de respuesta al acetato de glatiramero. | |
| UA95592U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95658U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95978U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95591U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106317U (uk) | Спосіб прогнозування зрощення перелому | |
| UA104418U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106318U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96535U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96284U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95654U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106731U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96640U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96666U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96985U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96635U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96679U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95622U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96127U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96077U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96943U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96935U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95642U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96667U (uk) | Спосіб прогнозування зрощення перелому |